Defendants AbbVie, Abbott Laboratories, and Unimed Pharmaceuticals filed an appeal in federal court in response to the final judgment in an antitrust case that found in favor of the Federal Trade Commission (FTC).
On July 18, AbbVie was found by a Philadelphia federal court to have instigated “sham litigation to illegally maintain its monopoly” over the testosterone replacement drug Androgel, according to a statement on the FTC’s website.
The US District Court for the Eastern District of Pennsylvania ordered the defendants to pay US$448 million to consumers, the largest award ever in in an FTC antitrust case.
The defendants’ appeal was submitted on August 6 by Munger, Tolles & Olson of Los Angeles. The defendants appealed to the US Court of Appeals for the Third Circuit.
Full Content: Legal News Line
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
